GP Dunn, N Sherpa, J Manyanga… - Advanced Drug Delivery …, 2022 - Elsevier
Malignant gliomas are the most common primary brain cancer diagnosed and still carry a poor prognosis despite aggressive multimodal management. Despite the continued …
TM Johanns, JP Ward, CA Miller, C Wilson… - Cancer immunology …, 2016 - AACR
The “cancer immunogenomics” paradigm has facilitated the search for tumor-specific antigens over the last 4 years by applying comprehensive cancer genomics to tumor antigen …
Glioblastoma (GBM) is resistant to multimodality therapeutic approaches. A high burden of tumor-specific mutant peptides (neoantigens) correlates with better survival and response to …
K Shetty, PA Ott - Annual Review of Cancer Biology, 2021 - annualreviews.org
Cancer vaccines can generate and amplify tumor-specific T cell responses with the promise to provide long-term control of cancer. All cancer cells harbor genetic alterations encoding …
Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt from central tolerance, can generate robust immune responses, and can function as bona …
Immunotherapy applications to glioblastoma represent a new treatment frontier. Antigen- targeted immunotherapy approaches hold enormous potential to elicit antigen-specific anti …
Purpose: The low mutational load of some cancers is considered one reason for the difficulty to develop effective tumor vaccines. To overcome this problem, we developed a strategy to …
E Blass, PA Ott - Nature reviews Clinical oncology, 2021 - nature.com
Within the past decade, the field of immunotherapy has revolutionized the treatment of many cancers with the development and regulatory approval of various immune-checkpoint …
V Leko, G Cafri, R Yossef, B Paria, V Hill… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
The adoptive transfer of naturally occurring T cells that recognize cancer neoantigens has led to durable tumor regressions in select patients with cancer. However, it remains …